Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)
- Registration Number
- NCT00543959
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
A study to evaluate the effectiveness and tolerability of MK0533 and pioglitazone in patients with type 2 diabetes mellitus.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 346
Inclusion Criteria
- Patients between the ages of 18 to 70 years with Type 2 diabetes who have not been able to adequately control their blood glucose levels
- Note: Only patients who have not been taking any antihyperglycemic medicine for 3 months will be screened
Exclusion Criteria
- Patients taking any medicines that affect body fluid level such as a diuretic or water pill
- Patients taking niacin or other certain medications
- Patients with any of the following conditions: liver or kidney disease, poorly controlled high blood pressure, heart disease or certain blood disorders
- Patients with abnormal laboratory results from a blood test that will be given before each patient starts the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Part 2 - Arm 2 MK0533 Part 2- Arm 2: drug 5mg Part 2 - Arm 4 MK0533 Part 2 - Arm 4: drug 30mg Part1 - Arm 1 MK0533 Part1: Arm 1: drug Part 2 - Arm 3 MK0533 Part 2 - Arm 3: drug 15mg
- Primary Outcome Measures
Name Time Method Body fluid gain from baseline after 12 weeks 12 weeks
- Secondary Outcome Measures
Name Time Method Fasting plasma glucose after 12 weeks 12 weeks